Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC3R | P41968 | 10/20 | 0.40 |
| ▸ | MC4R | P32245 | 9/20 | 0.40 |
| ▸ | MC1R | Q01726 | 1/20 | 0.40 |
| ▸ | MC5R | P33032 | 9/20 | 0.36 |
| ▸ | F2 | P00734 | 4/20 | 0.33 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 2/20 | 0.32 |
| ▸ | PLAT | P00750 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12387503 | 0.91 | MC3R (0.38) | MC3RMC4RMC1RMC5RF2 | |
| SCHEMBL13045405 | 0.89 | MC3R (0.43) | MC3RMC4RMC1RMC5RF2 | |
| SCHEMBL10085169 | 0.89 | MC3R (0.43) | MC3RMC4RMC1RMC5RF2 | |
| SCHEMBL12387488 | 0.89 | MC3R (0.43) | MC3RMC4RMC1RMC5RF2 | |
| SCHEMBL14524599 | 0.88 | MC3R (0.43) | MC3RMC4RMC1RMC5RF2 | |
| SCHEMBL16299312 | 0.87 | MC3R (0.42) | MC3RMC4RMC1RMC5RF2 | |
| SCHEMBL12387566 | 0.86 | MC3R (0.43) | MC3RMC4RMC1RMC5RF2 | |
| SCHEMBL12387461 | 0.86 | MC3R (0.43) | MC3RMC4RMC1RMC5RF2 | |
| SCHEMBL16299303 | 0.86 | MC3R (0.41) | MC3RMC4RMC1RMC5R | |
| SCHEMBL16315947 | 0.85 | MC3R (0.42) | MC3RMC4RMC1RMC5RF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027677-A1 | Prion-specific peptoid reagents | NOVARTIS AG | 2012-02-02 | — | — | US | disclosed |
| US-20120027677-A1 | Prion-specific peptoid reagents | NOVARTIS AG | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027677-A1 | Prion-specific peptoid reagents | PRNP, PARL, PCNP | MC3R 3280/4885MC4R 3225/4885MC1R 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.